FIELD: medicine.SUBSTANCE: invention represents a pharmaceutical composition for treating HIV infection as a solid dosage form containing at least one HIV protease inhibitor in a therapeutically effective amount specified in a group of nelfinavir sacvinavir tipranavir darunavir indinavir ritonavir lopinavir palinavir or fosamprenavir and pharmaceutically acceptable additives differing by the fact that the pharmaceutically acceptable additives are presented by at least one water-soluble polymer i...

The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-14-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease...

Crystalline salts polymorphs solvates and hydrates of bicalutamide 5-fluorouracil donepezil anastrozole nelfinavir mirtazapine lansoprazole and tamsulosin or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.

The present invention provides novel crystalline forms of Nelfinavir mesylate Form-A Form-B Form-C Form-D and the process for their preparation without the use of any special equipment such as a spray drier avoiding the use of highly flammable solvents such as ethers. The crystalline form can be tailored with the selection of the ante solvent and appropriate conditions for the process.

The present invention features conjugates of a somatostatin analog and anti-HIV agent (e.g. an HIV protease inhibitor (HPI) such as nelfinavir) and their use in the treatment of a patient (e.g. a human) infected with HIV.

The present invention features conjugates of a somatostatin analog and anti-HIV agent (e.g., an HIV protease inhibitor (HPI), such as nelfinavir), and their use in the treatment of a patient (e.g., a human) infected with HIV.

Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.

Crystalline salts polymorphs solvates and hydrates of bicalutamide 5-fluorouracil donepezil anastrozole nelfinavir mirtazapine lansoprazole and tamsulosin or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.